U.S. Food and Drug Administration Analysis of Newly Identified Adverse Events With Lurbinectedin: Extravasation, Rhabdomyolysis, and Tumor Lysis Syndrome
- Resource Type
- Source
- In
Clinical Lung Cancer December 2022 23(8):e556-e562 - Subject
- Language
- ISSN
- 1525-7304